New Drugs
| Brand/Generic | Company | Description |
|---|---|---|
|
Albrioza sodium phenylbutyrate/ursodoxicoltaurine |
Amylyx/Innomar Strategies | An oral combination that may reduce neuronal death in patients with amyotrophic lateral sclerosis (ALS). |
|
Bimzelx bimekizumab |
UCB Canada | A monoclonal antibody for moderate to severe plaque psoriasis. |
|
Breyanzi lisocabtagene maraleucel |
Celegene | An immunotherapy for B-cell lymphoma. |
|
Byooviz ranibizumab |
Biogen Canada | A biosimilar to Lucentis. |
|
Cibinqo abrocitinib |
Pfizer Canada | A Janus kinase-1 inhibitor for refractory, moderate to severe atopic dermatitis. |
|
Covifenz COVID-19 vaccine |
Medicago | A plant-based, recombinant, adjuvanted vaccine for prevention of COVID-19. |
|
Evusheld tixagevimab and cilgavimab |
AstraZeneca Canada | A combination monoclonal antibody for pre-exposure prophylaxis of COVID-19. |
|
HyQvia immunoglobulin/ hyaluronidase |
Takeda | A subcutaneous replacement therapy for immunodeficiencies. |
|
Letybo letibotulinumtoxinA |
Croma Aesthetics | A neuromuscular blocking agent to temporarily improve moderate to severe frown lines between the eyebrows. |
|
Nuvaxovid COVID-19 vaccine |
Novavax (US)/ Innomar Strategies | Adjuvanted vaccine for prevention of COVID-19. |
|
Ontruzant trastuzumab |
Samsung Bioepsis/ Organon | A biosimilar to Herceptin. |
|
Orladeyo berotralstat |
BioCryst/Innomar Strategies | An oral plasma kallikrein inhibitor to prevent hereditary angioedema. |
|
Oxlumo lumasiran |
Alnylam Netherlands/ Innomar Strategies | A glycolate oxidase reducer for primary hyperoxaluria. |
|
Palynziq pegvaliase |
Biomarin | An enzyme that reduces blood phenylalanine concentrations in phenylketonuria. |
|
Paxlovid nirmatrelvir/ritonavir |
Pfizer Canada | New oral antiviral for mild to moderate COVID-19 infection in patients at high risk for progression to severe COVID-19. |
|
Poteligeo mogamulizumab |
Kyow Kirin/Innomar Strategies | A monoclonal antibody for mycosis fungoides or Sezary syndrome. |
|
Prevnar 20 pneumococcal vaccine |
Pfizer Canada | 20-valent vaccine for prevention of pneumococcal disease. |
|
Rholistiq belumosudil |
Kadmon (US) | A protein kinase inhibitor for chronic graft-versus-host disease. |
|
Rybrevant amivantamab |
Janssen | A new monoclonal antibody for locally advanced/metastatic non-small cell lung cancer. |
|
Scemblix asciminib |
Novartis | A tyrosine kinase inhibitor for chronic phase chronic myeloid leukemia. |
|
Semglee insulin glargine |
BGP Pharma/Viatris | A biosimilar to Lantus. |
|
Simlandi adalimumab |
Jamp Pharma | A biosimilar to Humira. |
|
Slynd drospirenone |
Duchesnay | New progestin-only oral contraceptive. |
|
Sohonos palovarotene |
Ipsen | An oral retinoic-acid receptor gamma agonist for fibrodysplasia ossificans progressiva. |
|
Tabrecta capmatinib |
Novartis | New oral protein kinase inhibitor for non-small cell lung cancer. |
|
Tavneos avacopan |
Otsuka Canada | New oral complement 5a antagonist for active anti-neutrophil cytoplasmic auto-antibody associated vasculitis. |
|
Tezspire tezepelumab |
AstraZeneca Canada | A new monoclonal antibody for severe asthma. |
|
Vraylar cariprazine |
Allergan | New oral atypical antipsychotic for schizophrenia and bipolar I disorder. |
|
Welireg belzutifan |
Merck | An oral hypoxia-inducible factor 2 alpha (HIF-2α) inhibitor for von Hippel-Lindau disease-associated renal cell carcinoma. |
|
Xpovio selinexor |
Forus Therapeutics | An oral inhibitor of tumor suppressor proteins for multiple myeloma. |
| Brand/Generic | Company | Description |
|---|---|---|
|
Benvyon bendamustine |
Pfizer | A new solution formulation. |
|
Duokopt dorzolamide/timolol |
Thea Lab | A preservative-free formulation. |
|
Esamuze bendamustine |
Dr. Reddy’s | A concentrated bendamustine solution (requires dilution before IV infusion). |
|
Lumify brimonidine |
Bausch Health | A lower strength, over-the-counter ophthalmic solution. |
|
Zynrelef bupivacaine/meloxicam |
Heron Therapeutics (US) | A combination analgesic solution for surgical wound instillation. |
| Brand/Generic | Company | Description |
|---|